Journal Article

Will cancer stem cells provide new therapeutic targets?

Fariba Behbod and Jeffrey M. Rosen

in Carcinogenesis

Volume 26, issue 4, pages 703-711
Published in print April 2005 | ISSN: 0143-3334
Published online April 2005 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/bgh293
Will cancer stem cells provide new therapeutic targets?

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

This review presents a brief synopsis of recent progress in the area of cancer stem cells, with emphasis on leukemia and breast cancer, and discusses potential limitations to accomplishing the ultimate goal of eradicating residual disease in cancer.

Keywords: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCRP1, Breast Cancer Resistance Protein-1; CALLA, Acute Lymphoblastic Leukemia Common Antigen; CLP, committed lymphoid progenitor; CMP, common myeloid progenitors; EMA, Epithelial Membrane Antigen; EpCAM, epithelial cell adhesion molecule; ESA, epithelial-specific antigen; GMP, granulocytic/monocytic-restricted progenitors; Hh, Hedgehog; Hox, homeobox; HSCs, hematopoietic stem cells; LRP, Lung Resistance-Related Protein; LT, long-term progenitors; MEP, megakaryocytic/erythroid-restricted progenitors; MLL-ENL, Mixed Lineage Leukemia–Eleven Nineteen Leukemia; MMTV-Wnt-1, mouse mammary tumor virus promoter-driven Wnt-1; MUC-1, sialomucin; NOD/SCID, non-obese diabetic/severe combined immunodeficient; PDGF, Platelet-Derived Growth Factor; PTC-1, Patched-1; Sca-1, stem cell antigen-1; SL-IC, SCID leukemia-initiating cells; SP, side population; ST, short-term progenitors

Journal Article.  8990 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.